As 2023 draws to a close and companies finalise their Regulatory and Quality budgets for 2024, Arriello’s Kate Coleman assesses the trends topping the strategic agenda.
Tom Cowen, Head of Vertical Strategy, Healthcare & Life Sciences at Conga explores what happens when price transparency and government involvement goes too far and ways to prepare for this.
To develop cannabis products that can both enhance the quality of life of cannabis users and comply with current and future regulations, first we must understand what cannabis is, how people use it, and how it affects the human body and mind.
Stephan Ohnmacht and Werner Engelbrecht explore EMA’s vision of a single source of truth for clinical trial information forces a major shift in how companies collect and store trial data and documents.
At Amplexor’s recent BE THE EXPERT 2023 global conference, Remco Munnik of Iperion, discussed how good-quality data can be put to work to enhance internal and external processes, identifying new markets and reducing time to market.
Agnes Cwienczek, ALSS Head of Product Management and Consulting, ArisGlobal discusses the benefits of acting now to reap the benefits of eCTD 4.0 compliance.
Pete Lomas, Managing Consultant at Broughton, a scientific consultancy and contract research organisation, discusses how manufacturers can design vapes to improve their chances of MAA approval.
How can manufacturers leverage the proposed legislation to deliver needed treatments to patients in a way that is sustainable for long-term returns? Cem Zorlular, CEO of Er-Kim Pharmaceuticals explores.
Regulatory authorities have been focusing on safeguarding global supply chains. Juan Torrijos Lopez, GMP consultant at Rephine provides some practical pointers as to how pharmaceutical manufacturers should respond to evolving expectations.
Roberto Zerbi, global life sciences business development manager at industrial technology manufacturer Watlow, explains the challenge comes that come from developing the EudraLex Volume 4 Annex 1 guidance.
Cem Zorlular, CEO of Er-Kim Pharmaceuticals, shares his insights on how pharma manufacturers can better navigate the global commercialisation of treatments in an ever-changing landscape.
